Business Context and Reporting Period
This Form 6-K filing by Ping An Biomedical Co., Ltd. is dated May 27, 2026. The report addresses the Company's status regarding continued listing requirements on The Nasdaq Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance matters rather than financial performance data.
Material Changes and Listing Status
- Initial Deficiency: On November 24, 2025, the Company was notified by Nasdaq that it failed to meet the minimum bid price requirement of $1 per share under Rule 5550(a)(2) based on trading from October 10, 2025, to November 20, 2025.
- Compliance Extension: On May 26, 2026, Nasdaq granted the Company an additional 180-calendar-day compliance period, extending until November 23, 2026.
- Conditions for Extension: The extension was granted because the Company met the market value of publicly held shares requirement and all other initial listing requirements for the Capital Market, excluding the bid price. The Company also submitted a written notice of intent to cure the deficiency, potentially via a reverse stock split.
- Path to Compliance: The matter will be closed if the closing bid price reaches at least $1 per share for a minimum of 10 consecutive business days during this additional period.
Outlook, Risks, and Management Commentary
Management is currently evaluating options to regain compliance and intends to do so in a timely manner. However, the Company explicitly states that there can be no assurance it will be able to regain compliance with Rule 5550(a)(2) or maintain compliance with other Nasdaq continued listing requirements.
Investor Verification Checklist
- Verify the current stock price and whether it has sustained a $1.00 closing bid for 10 consecutive business days.
- Monitor for announcements regarding a potential reverse stock split to address the bid price deficiency.
- Confirm the Company's status regarding the market value of publicly held shares to ensure no new deficiencies arise.
- Review future filings for any updates on the November 23, 2026, compliance deadline.